Immunome Quarterly Balance Sheet
NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunome financial position
As of Jun 30, 2026, Immunome reported total assets of $565.4 million, up 90.8% from a year earlier against total liabilities of $40.3 million. Shareholders' equity stood at $525.1 million, or 92.9% of assets. The company held $217.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 15.08, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Immunome balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 217.71M | 582.69M | 653.48M | 272.64M | 143.88M | 257.61M | 143.35M | 155.57M | 165.33M | 269.72M | 98.68M | 90.64M |
| Short-Term Investments | 302.29M | — | 0 | 0 | 124.16M | 59.71M | 73.95M | 84.56M | 113.02M | 39.98M | 39.46M | — |
| Total Current Assets | 538.45M | 594.31M | 660.78M | 279.92M | 277.43M | 323.13M | 221.34M | 244.04M | 284.28M | 313.33M | 144.70M | 91.41M |
| Property, Plant & Equipment | 17.36M | 17.08M | 14.64M | 11.56M | 11.03M | 10.95M | 10.11M | 7.17M | 6.10M | 4.30M | 2.07M | 1.17M |
| Total Assets | 565.38M | 619.79M | 683.19M | 299.38M | 296.29M | 342.69M | 240.24M | 256.90M | 296.21M | 319.75M | 148.54M | 93.16M |
| Accounts Payable | 6.00M | 5.53M | 3.34M | 6.15M | 4.66M | 9.13M | 14.19M | 3.52M | 7.05M | 7.18M | 3.31M | 2.79M |
| Total Current Liabilities | 35.71M | 27.41M | 44.99M | 31.45M | 22.88M | 30.80M | 54.31M | 39.53M | 39.90M | 30.77M | 21.83M | 23.11M |
| Total Liabilities | 40.30M | 31.11M | 48.84M | 35.46M | 27.02M | 35.57M | 59.08M | 41.99M | 42.38M | 34.18M | 28.66M | 87.08M |
| Shareholders' Equity | 525.08M | 588.69M | 634.34M | 263.92M | 269.27M | 307.13M | 181.16M | 214.91M | 253.84M | 285.57M | 119.88M | 6.08M |
| Retained Earnings | -855.13M | -782.00M | -728.16M | -658.26M | -600.81M | -557.41M | -515.77M | -435.52M | -388.42M | -352.30M | -222.81M | -130.17M |
| Net Cash (Debt) | 520.00M | 582.69M | 653.48M | 272.64M | 268.04M | 317.32M | 217.30M | 240.13M | 278.35M | 309.71M | 138.14M | 90.64M |
| Shares Outstanding | 113.40M | 113.17M | 113.13M | 91.71M | 87.01M | 86.96M | 64.46M | 60.42M | 60.01M | 59.69M | 43.25M | 12.20M |
This table shows 12 quarterly periods of Immunome's balance sheet, from Q2 2026 back to Q3 2023, across 15 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow IMNM's reporting calendar. What is a balance sheet?